
Neuraxpharm pays US$650m for MS drug commercialisation
Together with a fee of US$12.5m for the launch of the B cell suppressant antibody to treat relapsing/remitting mulitple sclerosis (rMS), the US$140m...

Synbio experts develop cells that hear
Swiss researchers headed by synbio expert Martin Fussenegger have equipped designer cells with a bacterail ion channel that is responsive to...

Sygnature Discovery Ltd acquires leading Canadian CRO
The purchase of NuChem Sciences for an undisclosed sum is the third in a series of acquisitions in sixteen months as part of Sygnature's global...

BioLamina AB bags €19m funding for expansion
The tenth investement from Lauxera Capital Partners through its Lauxera Growth I fund will be usesd by the Swedish company to expand the development...

PureTech Health gets US$11.4m to advance LYT-300
PureTech Health plc has been awarded up to $11.4 million from the US government to advance LYT-300 (oral allopregnanolone) for the treatment of...

Aboleris Pharma bags €27.3m in Series A Financing
AbolerIS Pharma SA’s financing was led by Caixa Capital Risc and co-led by Sound Bioventures and existing investor Newton Biocapital with...

Living therapy: Microbial immunotherapy of Exeliom Biosciences gets a boost
Exeliom Biosciences (Paris, France) is using its unique knowledge of the microbiome-immunomodulation axis to develop next-generation immunotherapies....